Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study (NCT05914116) evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026 (February 26–28, 2026) and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028077), on February 23, 2026, and is solely responsible for the information contained therein.